EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

March 16, 2023

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 63 min

Earnings Call Speaker Segments

Nicola Fiore

unknown
#1

There may be situations that come up following today's date. Should you wish to pose a question, kindly reserve your spot through the chat with Bianca Fersini Mastelloni; following the booking order, she will gladly introduce you. Right now, though, I'd like to hand things over to Andrea Cangioli. Andrea, the floor is yours.

Andrea Cangioli

executive
#2

Good afternoon, everyone. Thank you, Nicola. Thank you, Bianca, for the introduction, and thanks to all of you for being with us on this earnings call following the release of the 2022 financials. Enrico Romagnoli and I are hosting this call on that topic. It goes without saying that we're very happy with the results we're discussing with you today for 2022, which once again delivered robust revenue growth of 18%, surpassing the EUR 673 million threshold. And most importantly, on margin, an excellent EBIT margin reaching the record level of 12%. We're also preserving our financial strength, one of the traditional cornerstones of how we approach the business, with a net financial position once again at roughly EUR 88 million at year-end. For today's call, we've chosen to change the usual agenda for the presentation. That concludes my very brief introduction. I'll ask Enrico to continue with a thorough review of the notable achievements of our 2022, and then we'd like to comment on the results with more of a forward-looking view on the current outlook. Thank you, Enrico, for continuing.

Enrico Romagnoli

executive
#3

Thanks, Andrea, and good morning, everyone. I'll share some thoughts on the financial results we released yesterday. The 2022 financial year wrapped up with an exceptionally strong outcome — our best ever, and comfortably ahead of the guidance. During the period, consolidated revenues came in above EUR 673 million, rising 18%, with double-digit expansion in both of our business sectors. Growth in the medical sector outpaced last year's by 23%, posting a 12% increase. Gross margin for the year reached EUR 249.7 million, up 17.7% from the EUR 212 million...

Bianca Fersini-Mastelloni

unknown
#4

My apologies, Enrico. My apologies — just one second, please. We’re picking up some noise. Could whoever it is kindly switch their microphone off? Please continue, Enrico.

Enrico Romagnoli

executive
#5

2 Thanks, Bianca. There's a great deal of background noise. All right. So where gross margin is concerned, the year ended at EUR 249 million versus EUR 212 million. The effect on sales is 37.1%, the same figure as last year. Operating expenses came to EUR 56.2 million, which is an absolute-value rise versus last year, yet with an unchanged impact on sales. The principal increases relate to commercial expenses, reflecting the return of international travel as well as trade fairs and congress activities, which is a meaningful cost, especially in the medical sector. Staff costs are rising as well, although their impact on turnover is improving slightly. As of December 31, the group had more than 2,100 employees. EBITDA reached EUR 95.2 million, 18.9% higher than last year's EUR 80 million, helped by higher turnover and better absorption of operating expenses. The EBITDA margin improved as well. Depreciation and provisions fell sharply, and as a result the EBIT margin rose from 11.4% to 12% for the current period. EBIT for the end of 2022 came to EUR 81 million, versus EUR 64.8 million a year earlier. Tax income, affected by a negative foreign exchange loss, was positive at EUR 78.9 million, with an 11.7% impact on turnover and an 18.9% increase.

Enrico Romagnoli

executive
#6

Net income came to EUR 55.1 million, equal to an 8.2% impact on turnover, which was a 21.3% increase. The tax rate for the year stood at 25%, compared with 26% last year. Turning briefly to the fourth quarter of 2022, sales grew 13.9%, and profitability in terms of gross margin, EBITDA and EBIT was in line with Q4 of 2021 — a robust quarter as a comparison, robust growth. On the balance sheet side, the group's net financial position at year-end was positive at roughly EUR 88.5 million, down EUR 27 million from the peak at the start of the year, yet up EUR 56 million from the lowest point at the end of September 2022. The rise in net capital employed also reflects the consolidation of KBF, the last Chinese company acquired at the end of December, with a net impact of EUR 10 million, including EUR 5 million of <<inaudible>>. Now to cash flow. As I already mentioned, during the year the net financial position declined by approximately EUR 27 million. Supply chain difficulties persisted throughout the year, and the need to lengthen the inventory cycle to give stability to the production process, together with the rapid growth achieved and expected, led to an expansion of working capital and the resulting use of cash of EUR 51 million.

Enrico Romagnoli

executive
#7

Operating investment for the year came to EUR 28 million. Cash was reduced by EUR 23 million for CapEx on new building plants and other fixed assets, with EUR 5 million of that relating to what would be paid for KBF. Dividends of EUR 70 million were paid during the year, EUR 60 million of which by <<inaudible>>, equal to EUR 0.20 per share. And yesterday, the Board of the Directors resolved to propose to the shareholder meeting <<inaudible>> a dividend of EUR 0.22 to be paid next May. As for the breakdown by business, growth achieved was significant across all market segments in which the group operates, and double-digit results were registered both in the medical sector, which grew by 23%, and in the industrial application sector, which showed a 4% increase. Aesthetics, accounting for 62.5% of the sector revenue, was the most important segment in the medical, showing growth of 20% and a turnover of approximately EUR 239 million. In aesthetics, sales performance was excellent in all main application segments — hair removal, removal of tattoos and pigmented lesions, body treatment and skin rejuvenation. The fastest growth was recorded in surgery, up 37%, with a result of EUR 62 million compared to EUR 45.2 million in the same period of last year, also exceeding the record levels achieved in 2019.

Enrico Romagnoli

executive
#8

We hit that goal in therapy as well, where turnover rose 17% to EUR 15.7 million, versus EUR 15.5 million in the same period of 2021. Aftersales service revenue climbed 19%, posting a sharp gain driven by growth in the installed base and, above all, by sales of optical fibers for urologic surgical application. The industrial sector was up 12%, a very positive result given the negative situation in the Chinese market. Slower growth in China's cutting segment did not hurt the overall result of the laser cutting division, which still posted a 13% rise in turnover thanks to the extraordinary performance of Cutlite Penta in Italy, Europe and in Brazil. The trend remained very positive in laser marking as well, helped by an acceleration in the second half of the year, reaching 5% growth over the year and EUR 25.4 million in turnover compared with EUR 24.2 million last year. After-service sales rose 24%, in line with growth in the installed base. Looking at sales by area across both sectors, the markets with the most brilliant result were Europe and the United States of America together with the Middle East.

Enrico Romagnoli

executive
#9

Just a handful of Far East regions posted weaker-than-anticipated results. As for China's industrial segment, the local economy's anticipated rebound, which underpinned the projected expansion for 2022 in laser cutting, was held back by continued anti-COVID restrictions tied to Chinese isolation and by the impact of the economic downturn, which hit our significant laser casting business unit. During 2022, our Chinese subsidiaries saw sales fall 16% in local currency, narrowed to 11.7% in Euro currency. Andrea, please go ahead on 2023 guidance.

Andrea Cangioli

executive
#10

Thank you. Thank you, Enrico. Following Enrico's presentation, I'd like to highlight and pull together some essential factors that made the extraordinary 2022 results possible, and to set them against where our markets stand now and how we are currently positioned. Let's begin with medical. Demand in the medical sector was stronger than ever in 2022. Purchase orders came at us all year long to the point that we were literally overwhelmed. And we raised our production capacity so as to boost the monthly throughput in terms of shippable units. We also sped up our purchasing schedules so as to get ahead of possible hiccups in our supply chains. The final balance, meaning the one at year-end, was a record production volume, record revenues and high raw material inventories. There were exceptions to this pattern, namely Asclepion, which was unable to fully prevent the supply chain failures and had to settle for a lower revenue growth in 2022. It was only 11.6% quoted, roughly 1/2 of the sector's average of over 22%. As a counterweight, Asclepion is showing today the largest backlog of unfulfilled demand and is the medical sector division with the best outlook for 2023. Moreover, while benefiting from a very strong order inflow, we managed to slightly increase our product prices for a significant part of our customers.

Andrea Cangioli

executive
#11

Like I mentioned, the order bookings volume isn't impacted, and the elevated backlog levels at year-end also include parts with adjusted — that is, higher — pricing. A major tailwind benefited us during 2022, namely foreign exchange movements. We enjoyed a conversion benefit from the renminbi, which appreciated and enables better conversion of the Chinese division's revenue results, despite their weakness. But the U.S. dollar especially was strong, consistently under $1.10 per euro, averaging $1.05 compared with $1.18 in 2021. Our revenue stated in U.S. dollars came to roughly EUR 90 million in 2022, producing approximately EUR 10 million in revenue translation benefit for 2022 against 2021. Because we pay a meaningful portion of our manufacturing parts and components in U.S. dollars, close to 2/3 of that amount is offset. So we were able to book about EUR 3 million as its contribution to gross margin and EBIT. Incidentally, since part of the balance expected in U.S. dollars has been recovered at around $1.10 per euro, you'll see the cost of the coverage in the financial expense line, which doesn't hit EBIT but affects net profit only.

Andrea Cangioli

executive
#12

The point I was trying to make with my final paragraphs is that 2022 was an exceptionally strong year for our medical business, and it makes for a very tough comparison when you set expected 2023 performance against it. During 2022, we dealt with the effects of the Ukrainian war on a business-by-business basis — at the start of the year it was throwing a shadow of uncertainty over how stable worldwide business activity would be, but we came through it successfully. Now in 2023, the economic climate is still carrying the weight of the Ukrainian war. But what we are seeing is the gathering and totaling up of effects set in motion in 2022 that did not need to have an immediate impact — they could not, except in specific business areas. I'm referring to the interest rate hike and how inflation affects cost and margins. Inflation effects. The way higher interest rates cool down the economy by making investment more difficult is, of course, a challenge in itself for capital equipment manufacturers, which is what we are. On top of that, as you know, the news flow coming from the banking sector over the last weeks does nothing to put the capital equipment customer at ease. Incidentally, I wanted to mention — and this may be of interest to you — that we hold no direct deposits in Silicon Valley Bank.

Andrea Cangioli

executive
#13

Also, we don't know of any of our customers who have direct deposits and are in any way tied to Silicon Valley Bank. Over the past few weeks, there has been a slowing in the pace of order intake and in requests for urgent deliveries, which had defined all of 2022 with respect to open orders, particularly from 2 significant areas of our business, the Middle East and the United States. Our guidance accounts for the difficulties in further accelerating our medical revenues in 2022. The good news here is that the fundamental drivers of our midterm market growth remain the same, and we anticipate another very strong year in absolute value. The 2022 story is quite different in the industrial sector. As you just heard from Enrico, while we ran at full speed worldwide in the medical sector, in the industrial sector, and specifically in the laser cutting business, we experienced a severe downturn in China, our most important market. A downturn that was more than compensated for by the fantastic growth recorded in the other markets, in Italy first of all and in Europe as well. Our revenue and profitability targets were substantially missed in China, and you have heard the reasons why.

Andrea Cangioli

executive
#14

Yet the marking segment contributed favorably as well, so the industrial division's overall outcome added to both revenue and profit growth, and China's deceleration did not stop us from reaching our consolidated targets and records. In the cutting business, we now anticipate a year of very robust rebound in the Chinese market, unshackled from the constraints and obstacles we endured during 2022. For the entire country, and for us specifically, reversing the downward trajectory left by the exceptionally weak fourth-quarter 2022 performance will, I believe, require some time — a few months. Still, we and the business community in China are banking on a very strong 2023. Meanwhile, in this part of the world — Italy and Europe, where I am at present — we intend to increasingly capitalize on our penetration of the European and North American markets, and we are preparing strong international expansion in the business that will more than offset the expected softening of the Italian market caused by the smaller tax incentive permitted for technological investment, the so-called Industry 4.0 tax cuts.

Andrea Cangioli

executive
#15

In addition, we expect the marking segment to make a positive contribution to growth in both revenue and profit during 2023. We are beginning to reap the benefits of the substantial investments we have made over recent years in technical and sales capabilities. One sector deserves a mention on this call: its overall size is roughly EUR 30 million, and the investment in the new facilities in Torre Annunziata — I'm referring to the company <<inaudible>> — along with the new subsidiaries in Poland and Spain, should not become materially productive. Turning back to the cutting business, here is an overview and update on the process we launched some time ago, aimed at raising the organization to the standards needed to file for an IPO in Mainland China. Those standards involve requirements of several kinds; we have streamlined the relevant unit by placing Cutlite Penta Italy and Cutlite Brazil under the control of <<inaudible>>. We now have a group of financial investors alongside us as shareholders, and we are bringing our control and reporting procedures into line with the specific local standards for public companies. But most importantly, we are working hard to reach the profitability level that makes the entire process possible and meaningful, and positive market trends did not support us over the last 18 months — though they can in the coming 12.

Andrea Cangioli

executive
#16

Back in December, we bought a controlling stake in KBF — a Shenzhen-based firm that focuses on designing and building laser-based production lines for electric-vehicle batteries. We chose to make a distinct move in this adjacent market, which offers very strong growth potential, and we're relying on the revenue and profit contribution that comes from this business and adds to our results. To sum up where Industrial stands right now, we're looking at a year of robust expansion, and that's what the opening week of the year is already suggesting. On the medical side, constraints on credit availability — ranging from elevated interest rates all the way to the severe risk that a credit crunch could pose to the market — might hold back the development path we expect. That said, as of today we aren't seeing any meaningful negative impact. The guidance we issued yesterday is our first yearly outlook, so it's cautious given how our order backlog behaves — which, as you're aware, is very strong and substantial right now. Yet, as you know, it usually spans just a few months of production and sales. That guidance called for revenue growth on a consolidated basis without stating how much revenue would rise, and it sets a profit target as confirmation of the EBIT recorded in 2022.

Andrea Cangioli

executive
#17

Of course, that means EBIT margins will be lower because of the mix effect, as the industrial sector is expected to carry more weight. And it also reflects our current projections for gross margins and the leverage effect — which, at the moment, we see as solid, though not backed by the tailwinds that gave us a lift in 2022; instead, we're up against the headwinds I mentioned earlier. Those headwinds, I want to be clear, aren't specific to any market, and they aren't even specific to our position — a position where we feel stronger and more positive all the time — they come from the broader economic environment. Before we open the question-and-answer section, I'd like to leave you with 2 comments. The company and the group feel extremely strong and well positioned to seize the growth our markets are expected to deliver in the years ahead, and we're confident of another year with very strong profitability as well as growth. We decided — the Board of Directors decided to propose for shareholder approval a dividend of EUR 0.22 per share, which is a 10% increase over the dividend paid in 2022. At this point, my presentation is finished, and we'll be glad to take your questions.

Bianca Fersini-Mastelloni

unknown
#18

Alright, let's begin with the Q&A portion, and we have 3 questions on our list. The first comes from Giovanni Selvetti at Berenberg. <<operator_script>>

Giovanni Selvetti

analyst
#19

Okay, so I think the primary concern right now centers on the 2023 guidance, and I'm trying to get a handle on where things actually stand. As you mentioned earlier in both the press release and the presentation you shared, you're describing not only a decline in EBIT margins — because if EBIT stayed flat while revenues rose, margins would naturally compress as a result — but you're also indicating that EBIT will fall in absolute terms. From your presentation, it now looks like the bulk of the difficulties stem from the medical division. So my first question is whether you're already seeing any indication of a slowdown, given that leases are presumably costing more because of higher interest rates, and to what degree is that weighing on demand? Also, because when I look at the full year results, the implied growth for Q4 was still really, really strong. So a massive drop in the first quarter of the year would surprise me. The second question concerns the Chinese market. You said the fourth quarter was still affected by the lockdowns. I'd just like to get, again, a sense of how the situation looks there in the first quarter of the year, and what we should expect?

Giovanni Selvetti

analyst
#20

Also, if the — again, this ought to accelerate the potential reopening of the process for listing the cutting division. So what’s the timeline on that? My third question concerns Accure. Could you give us an update, and when might this product begin bringing in revenues? I mean the acne treatment laser that received FDA authorization before Christmas. And my last question is about cash. You mentioned that, naturally, cash took a hit in 2022 because inventories rose sharply to satisfy demand. So, given the present conditions and the guidance you’re providing now, with aesthetics demand slowing, can we expect the cash balance to increase? And what level of CapEx should we anticipate for 2023?

Andrea Cangioli

executive
#21

Alright, thank you, Giovanni. To start with the EBIT margin — and this is precisely because we're laying out, in some way, a flat EBIT margin as a target, meaning EBIT, sorry — there are several negative factors at play that are pushing the EBIT margin down and, as a result, lowering EBIT, even while we're projecting revenue growth. Mix is the biggest one. We intend to grow, though we're not stating today what the growth figure will be, but we're anticipating quite a pronounced expansion in the industrial business, which carries lower profitability margins. So that's a mix effect, and it makes up one part. The second part is that because of inflation, and because it won't be possible to count on a foreign exchange tailwind again in 2023, even with the same volumes we'll see a lower gross margin on the medical side. We've added production capacity. So unless we raise volumes by a certain amount, we also get less benefit from the leverage effect. Thus, the fact that we aren't projecting very rapid growth today in our forecast also weighs on EBIT margins.

Andrea Cangioli

executive
#22

Still, I think the margins we're mapping out today are excellent margins. Compared with our history, they're naturally below where we stood in 2022. But then again, 2022 gained from a set of very, very, very favorable circumstances that, let's say, we can't count on for 2023 at this point. The IPO in the industrial business. That IPO is something we're working on, and we're putting in a great effort so that, as an organization, we're ready in every detail. We had those equity funds, those private equity funds, coming into our capital, and that's a prerequisite. We're working on the timeline in which we might proceed with a filing, and hopefully that comes when we begin to see a genuine return to rapid growth and profitability. So our hope is that this happens before the end of this 2023. Accure is, as you know, that related company which raised a certain sum of money to develop distribution of the Accure laser, which Penta system has developed. They obtained -- we obtained the FDA clearance in late 2022, and at this point we're ready for commercialization. The strategy right now is to go for...

Andrea Cangioli

executive
#23

<<inaudible>>.

Giovanni Selvetti

analyst
#24

Andrea, I've lost the audio from you. It seems to me that...

Andrea Cangioli

executive
#25

I'm not sure what happened. You can hear me now, right? <<foreign_lang>> Something popped up on my screen and I wasn't audible anymore. Accure. So the plan is to bring to market a first batch—a fairly substantial one—of pilot devices, and then in a second phase to approach the market more forcefully. Our 2023 budget, as a result, doesn't include any big splash for this device, nor for the revenue it generates, which per our plans is expected to come later in the year, with a limited effect on 2023 and a stronger effect anticipated in 2024. Cash. You're right. I mean, your assumption—excuse me. All the assumptions you laid out in your question are correct. We raised inventory on the basis of the higher volume and the longer transit time of production at the factory, driven by the need to buy materials earlier so as to prevent delays from our suppliers. We are planning our revenue growth, and we have purchased a second house so that we can have revenue growth in terms of production volumes. If production volumes fail to meet the expected growth, we would have, at first, an increase in inventory, and then we would readjust the purchasing volume.

Andrea Cangioli

executive
#26

But sadly, with the way the purchasing market and, let's say, the supply situation stand right now, we can't come anywhere near what you'd describe as a just-in-time purchasing strategy, because if we bought just in time, put simply, we would not be in a position to deliver. So we have to take a position on raw materials so that we're able to manufacture more across the year. And this may show up as higher inventories if we can't sell more than -- sell the quantities we've scheduled for production. The good news on that front is there's no obsolescence risk, since what we're buying is for our mainstreams, which, I mean, if we don't produce it in Q1, we'll produce it in Q2, Q3 or whatever. We don't have production -- shifts in our production structure that would cause our components to become obsolete very rapidly. In fact, what we're facing more is something different: we're seeing more obsolescence in the sense that certain suppliers are cutting production of certain components, and we need to design around the components that are missing, that are becoming obsolete, so we can continue the productions we have and that rely on certain technologies. So the risk isn't -- it's more on the purchase side than on the sales side.

Andrea Cangioli

executive
#27

Finally, on CapEx. We have an investment plan for 2022 — '23, sorry — and it's aggressive, but CapEx as of today, even though we're planning to expand our building surface here in Florence and to keep expanding the available surface and to set up the production facilities we have around the world, is currently scheduled to come in lower than in 2022. In 2022 we had roughly EUR 22 million of investment in fixed assets, Enrico?

Enrico Romagnoli

executive
#28

Yes.

Andrea Cangioli

executive
#29

Of that EUR 22 million, roughly EUR 15 million goes toward new buildings and revamping existing ones. The EUR 7 million that isn't in buildings, I think, will stay more or less as they are — perhaps rising by EUR 1 million. That's the current plan. Meanwhile, the EUR 15 million for building revamping should come to about 1/2 of that amount, or just slightly above it. Naturally, if investment opportunities come our way, we'll seize them, because here in Florence we're somewhat constrained in how far we can expand. And in the past, we've had to capitalize on certain neighboring — certain neighbors selling their plants and deciding, one way or another, to buy it. It wasn't in the plans, but it was an effective investment. I believe that answers your questions.

Giovanni Selvetti

analyst
#30

Right. Perhaps only regarding that first item, though. I’m not sure I caught everything you said. But are you beginning to observe customers delaying purchases in that area as a result of higher leasing costs, within the medical segment?

Andrea Cangioli

executive
#31

More leases — your — this is likely tied to the softening we're observing. Actually, I mean, there are 2 components here. The first is credit being unavailable, which would be worse, but that isn't happening as far as we can see; the second is postponement — when instead of paying 4%, you're asked for 6%, 7%, you become a bit, let's say, uncertain and you somehow put things off. Yes, that is having an effect, that is definitely having an effect. Our way of competing is through innovation and by making our sales proposition even more appealing to customers. Another possible effect at some point could be making the offer more attractive by cutting the price a little, by helping customers pay higher interest through, in effect, discounting. Previously, in Italy, we had several times the offers that are typical in the consumer market as well, the so-called 0 interest offer. So — but you know what a 0 interest offer is. It's essentially a discount on the lease units so that in this way they can avoid charging any interest to the customer, but because it pays less for the unit from the supplier. Have I answered your question now?

Giovanni Selvetti

analyst
#32

Yes, that's clear enough. Thanks.

Bianca Fersini-Mastelloni

unknown
#33

Andrea, our next question is from François Robillard at Intermonte.

François Robillard

analyst
#34

Let me start with the first one, which goes back to your top line and the growth expectations for next year. Basically, aside from worries about demand falling off and without favorable foreign exchange conditions returning, I think I understand that your order books are still at fairly high levels. Plus, we've seen peers such as in the medical segment guiding plus 16% for next year, and Bystronic, which is also positive on growth. So should I take it that your guidance is fairly cautious because of a possible slowdown in the second half? And how much of that are you already seeing today? That's my first question. My second question is on supply chain. You already answered part of Giovanni's question on that. Just on freight costs — those have come down quite a lot over the last few months. How will that affect your cost structure going forward, and what was the effect of freight cost inflation in 2022? And should we expect this to go away in 2023? That's my second question. Then a third question. So if I understood correctly from your presentation, you are intending to start selling industrial products as well in the U.S.

François Robillard

analyst
#35

So that would offset weaker demand in Italy. Is that right? And if that’s the case, will the products headed for the U.S. market be made in China or at your Italian plants? And last, a quick 1 on financial costs. We’re seeing a pretty sharp jump in the fourth quarter. Could you give us more detail on what drove that acceleration in financial costs in Q4? And should we expect that to continue in 2023?

Andrea Cangioli

executive
#36

All right. So first, the guidance—if we anticipate a slowdown, if being prudent makes sense, or if it doesn't, how should we think about our backlog? We're right at the start of the year. Being prudent is necessary, because—look, if I said our order backlog sits 10% above where it stood at the start of 2022, I wouldn't be wrong. What matters, though, isn't just the backlog itself—it's how that backlog turns into orders, how fast that conversion happens, and how hard customers are pushing for deliveries. So unfortunately, because our orders aren't secured by a letter of credit that fixes a precise delivery date backed by financial collateral, the order volume tells us there's strong demand expected over the coming months. But it doesn't—what really sets the pace is what's actually happening in the market. And given that we've observed a slowdown in recent weeks relative to the genuine hunger we saw during the months of 2022, we chose to be more cautious—particularly in the medical sector—when laying out the volumes we expect for 2023.

Andrea Cangioli

executive
#37

On the supply side and how inflation affects us and whether we can counterbalance it — if I understand your question correctly, François — our manufacturing costs have gone up gradually. We attempted to offset some of that rise through production efficiencies, since higher volumes in 2022 boosted production efficiency and in a way lowered our cost of goods sold, and also through price increases. As you move into 2023, I don't detect any easing of inflation. It remains present. Our vendors keep applying price increases to us, perhaps less sharply than they did during certain months of 2022, but inflation has not disappeared. As I told you, we raised our price list, so in theory our prices are higher relative to what we were charging in 2022. That ought to let us offset part — at least partially — of the cost increase. But as I said when responding to Giovanni Selvetti, if we run into softness, if we have issues with our customer funding, we would likely be compelled to be more aggressive with our pricing and surrender a certain margin point to ensure we sustain the volumes, which granted the leverage effect, which lets us maintain more interesting EBIT levels.

Andrea Cangioli

executive
#38

On U.S. capping — yes, that's correct. We've begun selling into the United States, and at the same time we're raising sales volumes in Europe to offset the anticipated deceleration in growth, the anticipated deceleration in growth of sales on the Italian market stemming from the impact of changes to the Italian government's tax policies. At present, our approach is to sell into the U.S. from Italy. We don't consider it appropriate right now to set up any commercial relationship between China and the United States — not because it wouldn't be profitable, but because we believe we can be profitable well enough by shipping the European product, which at this moment enjoys a much higher level of acceptance in the United States.

François Robillard

analyst
#39

And what kind of scale are we talking about for that opportunity? Could you tell us what target you have in mind for U.S. cutting sales in 2023 and beyond?

Andrea Cangioli

executive
#40

We aren't — perhaps as the year goes on, we'll have more detail. Right now, we can't break it down by individual market. That's also because, well, we aren't designing a market launch that would represent, let's say, 20% of our sales. We're going to enter the market gradually. We're aiming to raise the overall share of exports for products made in Italy, but giving precise country-by-country guidance wouldn't be appropriate. We intend to perform well. It's going to be — I mean, we had a handful of units in 2022, and we won't reach tens of units in 2023, but it would support the sales growth we anticipate for the industrial market in 2023.

François Robillard

analyst
#41

Apologies — one final question about the financial costs in Q4.

Andrea Cangioli

executive
#42

Let's talk about financial cost. As for why it's higher in Q4, maybe Enrico can explain that. The bulk of the financial cost comes from foreign exchange. The reason it was higher probably has to do with how foreign exchange behaved. Enrico?

Enrico Romagnoli

executive
#43

Yes, more or less — the bulk of those financial costs come from foreign exchange losses, and that's mainly tied to the U.S. dollar, because at the close of Q3 the U.S. dollar stood below the unit we compare it against, the euro. Right now we're at roughly 0.9 — 0.95, 0.97. When the year ended, the U.S. dollar was above 1. So today we're sitting around 1.05, 1.06. That means the largest share of the expense relates to foreign exchange losses between the euro and the U.S. dollar.

Bianca Fersini-Mastelloni

unknown
#44

Andrea, there are 3 more questions. The first comes from Antoine Fournier. Please go ahead, Antoine. Antoine, are you still with us? Perhaps not. Okay. Then let's continue with Andrea Bonfa from Banca Akros, please.

Andrea Bonfà

analyst
#45

So now, my question again has to do with the guidance. A lot of it has already been gone through and explained. Even so, I want to make sure I've properly grasped <<inaudible>> growth. So EBIT for the industrial division should stand. But regarding medical, if I got that right, you see, sorry?

Andrea Cangioli

executive
#46

I’m having trouble hearing you—it’s the microphone.

Andrea Bonfà

analyst
#47

Apologies, apologies — my mic wasn't plugged in properly. Sorry, let's begin again. So I've been attempting to get a clearer picture of your guidance. The industrial laser division is growing, then. On that front, there's no significant problem for this year. We're waiting on and factoring in the Chinese recovery. But regarding medical, if I've understood you right, you're anticipating moderate growth — yet let's say, is that the kind of growth where inflation ends up being part of that expansion at the end of the day? Is that more or less accurate? And assuming that's accurate, my assumption is that in 2022, ForEx was a meaningful tailwind for your profitability. And if you can, could you quantify the ForEx contribution at the EBIT level for 2022?

Andrea Cangioli

executive
#48

To begin with, yes — I can confirm that my guidance is stated in nominal terms. What I mean is that it reflects nominal value. So it isn't expressed in volumes; it's expressed in euros, and as a result, it takes into account price increases wherever we have implemented them. On the subject of foreign exchange, during my presentation I walked through a rough analysis of how FX contributed to the EBIT margin and the gross margin. I estimate the tailwind at roughly EUR 3 million, which sits in gross margin and in EBIT margin, and 50% of it flows through to net profit, because for about 50% there is the cost of the coverage — a cost, since we hedged at 1.10. We hedged at 1.10 when the dollar stood at 1.13, and after that the dollar fell to 1.2, close to 1, so we incur a cost on the coverage. That is the overall ForEx effect in 2022. Is that clear?

Andrea Bonfà

analyst
#49

All right. But suppose those are the figures, right? Yes. And yet, if those are the figures, there isn’t a really huge effect on your profitability for last year. So then, regarding your guidance, when all is said and done, inflation is the biggest headwind, since, I mean, you anticipate robust growth in industrial. In America, you expect nominal top line growth in any case. It will be modest — that’s what we’re seeing — yet you do expect top line growth, while your guidance points to a lower EBIT. So when everything is said and done, it’s your cost base, which is growing faster than inflation overall. In a nutshell, is that right?

Andrea Cangioli

executive
#50

It -- what I mean is, on the low end of what we projected, that's right, since at the low end of the projections, which we shared right at the very end, we didn't want our guidance to be overly optimistic at the start of the year, as has always been our approach. Gross margin gets eroded by mix, and EBIT margin also gets eroded by leverage, and leverage occurs even at constant volumes because costs are rising. Incidentally, in Italy we will see wages go up by an average of 2.5% owing to the 5% cost increase coming our way from June as a result of the revised national agreements in our sector. So fixed costs are climbing, and achieving that same leverage effect on EBIT at unchanged volumes will be tougher for us. Naturally, had we -- if we had shared guidance that was more optimistic. Of course, there's a range in what we see happening during the year. The better we perform, I mean, if volumes rise, that is more than linearly accretive to EBIT thanks to the leverage effect. We need to be -- we chose to stay cautious at this point in the year, since the year is long.

Andrea Cangioli

executive
#51

The economic backdrop did not get off to a good start. Our positioning, though, and the sentiment we share with customers began on a strong note. As I mentioned, however, as the weeks passed we sensed that uncertainty—driven by certain financial factors such as interest rates and, more recently, by the fresh shock created by the bank's bankruptcy—had somewhat dampened customer confidence. We hold a very positive view that developments will trend favorably through the year. Still, within our range of expected results, we prefer to remain cautious in what we deliver to the market today, as you know, consistent with how we have always begun at the start of the year.

Bianca Fersini-Mastelloni

unknown
#52

Andrea, Victoria has one final question for us — the last one, from Victoria Konstantinova of Victory Capital. Victoria ? <<foreign_lang>>

Andrea Cangioli

executive
#53

Her mic is live.

Bianca Fersini-Mastelloni

unknown
#54

Yes, yes — on Victoria's question, hold on a second. Let me read it out for you. <<foreign_lang>> Victoria, I'll read your question aloud, one moment. Okay. So this is what Victoria asks: do you expect medical sales to stay flat or go up in 2023, and which areas of aesthetics do you think will be hit the hardest?

Andrea Cangioli

executive
#55

Yeah, the plan behind the guidance we put out assumes moderate growth in the medical segment. That comes from stronger growth in some areas, along with slower growth and flatness in others. Urology and dermatology are the areas where we're projecting the most growth. The area where we see the fewest opportunities to expand our production volume further is hair removal, and that's the segment where we recorded the biggest growth in 2022. Hello?

Bianca Fersini-Mastelloni

unknown
#56

I'm turning it over to Victoria to see whether she has another question. No, thank you. So, Andrea, there are no further questions on our list. Therefore, if investors have nothing more to ask, we'll bring this conference to a close. Should you have any additional questions you'd like to look into, please feel free to reach out to Enrico Romagnoli, who will be glad to answer them. Thank you to Andrea Cangioli and Enrico Romagnoli, and thanks to every investor who joined this conference; we hope to see you all again next time. Good afternoon, everyone. Bye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.